Cost-utility analysis of pembrolizumab versus nivolumab in the treatment of metastatic colorectal cancer from the perspective of the healthcare payer
Int. Journal of Clinical Pharmacology and Therapeutics · 2025
DOI: 10.5414/cp204665 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2025. Verfasst von Zhen Lu und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Colorectal Neoplasms, Drug Costs.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Lu, Z., Huang, X., Ou, Y., Wang, Q., & Tan, Q. (2025). Cost-utility analysis of pembrolizumab versus nivolumab in the treatment of metastatic colorectal cancer from the perspective of the healthcare payer. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204665
Vancouver
Lu Z, Huang X, Ou Y, Wang Q, Tan Q. Cost-utility analysis of pembrolizumab versus nivolumab in the treatment of metastatic colorectal cancer from the perspective of the healthcare payer. Int. Journal of Clinical Pharmacology and Therapeutics. 2025. doi:10.5414/cp204665
BibTeX
@article{Lu2025,
author = {Lu, Zhen and Huang, Xiaoyan and Ou, Yingjuan and Wang, Qinbo and Tan, Qirong},
title = {Cost-utility analysis of pembrolizumab versus nivolumab in the treatment of metastatic colorectal cancer from the perspective of the healthcare payer},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2025},
doi = {10.5414/cp204665}
}
EUVIMED